312 related articles for article (PubMed ID: 33249060)
1. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines.
Luban J; Sattler RA; Mühlberger E; Graci JD; Cao L; Weetall M; Trotta C; Colacino JM; Bavari S; Strambio-De-Castillia C; Suder EL; Wang Y; Soloveva V; Cintron-Lue K; Naryshkin NA; Pykett M; Welch EM; O'Keefe K; Kong R; Goodwin E; Jacobson A; Paessler S; Peltz SW
Virus Res; 2021 Jan; 292():198246. PubMed ID: 33249060
[TBL] [Abstract][Full Text] [Related]
2. The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines.
Luban J; Sattler R; Mühlberger E; Graci JD; Cao L; Weetall M; Trotta C; Colacino JM; Bavari S; Strambio-De-Castillia C; Suder EL; Wang Y; Soloveva V; Cintron-Lue K; Naryshkin NA; Pykett M; Welch EM; O'Keefe K; Kong R; Goodwin E; Jacobson A; Paessler S; Peltz S
bioRxiv; 2020 Aug; ():. PubMed ID: 32793904
[TBL] [Abstract][Full Text] [Related]
3. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
4. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
[TBL] [Abstract][Full Text] [Related]
5. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Cao L; Weetall M; Trotta C; Cintron K; Ma J; Kim MJ; Furia B; Romfo C; Graci JD; Li W; Du J; Sheedy J; Hedrick J; Risher N; Yeh S; Qi H; Arasu T; Hwang S; Lennox W; Kong R; Petruska J; Moon YC; Babiak J; Davis TW; Jacobson A; Almstead NG; Branstrom A; Colacino JM; Peltz SW
Mol Cancer Ther; 2019 Jan; 18(1):3-16. PubMed ID: 30352802
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
Berber B; Doluca O
Brief Bioinform; 2021 Mar; 22(2):1023-1037. PubMed ID: 33406218
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic drug-drug interaction study between rosuvastatin and emvododstat, a potent anti-SARS-CoV-2 (COVID-19) DHODH (dihydroorotate dehydrogenase) inhibitor.
Morton TL; Laskin OL; Kaushik D; Lee L; Ma J; Kristensen A; O'Keefe K; Golden L; Klein M; Kong R
Pharmacol Res Perspect; 2023 Apr; 11(2):e01076. PubMed ID: 36938928
[TBL] [Abstract][Full Text] [Related]
8. Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro.
Kim YJ; Cubitt B; Cai Y; Kuhn JH; Vitt D; Kohlhof H; de la Torre JC
Viruses; 2020 Jul; 12(8):. PubMed ID: 32751087
[TBL] [Abstract][Full Text] [Related]
9. Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
Luganini A; Sibille G; Mognetti B; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Gribaudo G
Antiviral Res; 2021 May; 189():105057. PubMed ID: 33716051
[TBL] [Abstract][Full Text] [Related]
10. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC
Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990
[TBL] [Abstract][Full Text] [Related]
11. DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.
Kayamori K; Nagai Y; Zhong C; Kaito S; Shinoda D; Koide S; Kuribayashi W; Oshima M; Nakajima-Takagi Y; Yamashita M; Mimura N; Becker HJ; Izawa K; Yamazaki S; Iwano S; Miyawaki A; Ito R; Tohyama K; Lennox W; Sheedy J; Weetall M; Sakaida E; Yokote K; Iwama A
Blood Adv; 2021 Jan; 5(2):438-450. PubMed ID: 33496740
[TBL] [Abstract][Full Text] [Related]
12. Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
Demarest JF; Kienle M; Boytz R; Ayres M; Kim EJ; Patten JJ; Chung D; Gandhi V; Davey RA; Sykes DB; Shohdy N; Pottage JC; Kumar VS
Antiviral Res; 2022 Oct; 206():105403. PubMed ID: 36041646
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis.
Wang QY; Bushell S; Qing M; Xu HY; Bonavia A; Nunes S; Zhou J; Poh MK; Florez de Sessions P; Niyomrattanakit P; Dong H; Hoffmaster K; Goh A; Nilar S; Schul W; Jones S; Kramer L; Compton T; Shi PY
J Virol; 2011 Jul; 85(13):6548-56. PubMed ID: 21507975
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.
Luthra P; Naidoo J; Pietzsch CA; De S; Khadka S; Anantpadma M; Williams CG; Edwards MR; Davey RA; Bukreyev A; Ready JM; Basler CF
Antiviral Res; 2018 Oct; 158():288-302. PubMed ID: 30144461
[TBL] [Abstract][Full Text] [Related]
16. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses.
Schreiber A; Viemann D; Schöning J; Schloer S; Mecate Zambrano A; Brunotte L; Faist A; Schöfbänker M; Hrincius E; Hoffmann H; Hoffmann M; Pöhlmann S; Rescher U; Planz O; Ludwig S
Cell Mol Life Sci; 2022 Jan; 79(1):65. PubMed ID: 35013790
[TBL] [Abstract][Full Text] [Related]
17. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Lim YS; Nguyen LP; Lee GH; Lee SG; Lyoo KS; Kim B; Hwang SB
Mol Cells; 2021 Sep; 44(9):688-695. PubMed ID: 34518443
[TBL] [Abstract][Full Text] [Related]
18. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
19. A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses.
Zheng Y; Li S; Song K; Ye J; Li W; Zhong Y; Feng Z; Liang S; Cai Z; Xu K
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632670
[TBL] [Abstract][Full Text] [Related]
20. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M
Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
